AAHI-SC3 Vaccine / ImmunityBio - LARVOL DELTA

THEMBA II T-Cell Vaccine: Vaccination With saRNA COVID-19 Vaccines (clinicaltrials.gov) - P1/2 | N=60 | Terminated | Sponsor: ImmunityBio, Inc. | N=180 ➔ 60 | Trial completion date: Sep 2023 ➔ Mar 2024 | Recruiting ➔ Terminated | Trial primary completion date: Sep 2023 ➔ Mar 2024; Discontinued prior to enroll in Phase 2

Enrollment change • Trial completion date • Trial primary completion date • Trial termination • Infectious Disease • Novel Coronavirus Disease

THEMBA II T-Cell Vaccine: Vaccination With saRNA COVID-19 Vaccines (clinicaltrials.gov) - P1/2 | N=180 | Recruiting | Sponsor: ImmunityBio, Inc. | Trial completion date: Jun 2023 ➔ Sep 2023 | Trial primary completion date: Jun 2023 ➔ Sep 2023

Trial completion date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease

THEMBA II T-Cell Vaccine: Vaccination With saRNA COVID-19 Vaccines (clinicaltrials.gov) - P1/2 | N=180 | Recruiting | Sponsor: ImmunityBio, Inc.

New P1/2 trial • Infectious Disease • Novel Coronavirus Disease